EF Hutton Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Elemer Piros has reiterated a 'Buy' rating on ATAI Life Sciences, maintaining a price target of $15.
August 09, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst has reiterated a 'Buy' rating on ATAI Life Sciences, maintaining a price target of $15.
The reiteration of a 'Buy' rating by EF Hutton indicates a positive outlook for ATAI Life Sciences. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100